Importantly, the intratumoral heterogeneity of HER2-positive breast cancers with respect to tumor genomics significantly affected the probability of achieving a pathological complete remission following neoadjuvant therapy that is based on chemotherapy and HER2 targeting with specific monoclonal antibodies [85]. This evidence concerns the gene ERBB2 and breast cancer.